Monoclonal antibody therapies against SARS-CoV-2.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 35803289.
- Also identified by DOI 10.1016/S1473-3099(22)00311-5 and PMC identifier 9255948.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Monoclonal antibodies (mAbs) targeting the spike protein of SARS-CoV-2 have been widely used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs and their effect as therapeutics in the pandemic, including structural classification, outcomes in clinical trials that led to the authorisation of mAbs, and baseline and treatment-emergent immune escape. We show how the omicron (B.1.1.529) variant of concern has reset treatment strategies so far, discuss future developments that could lead to improved outcomes, and report the intrinsic limitations of using mAbs as therapeutic agents.
Medical subject headings
- SARS-CoV-2
- COVID-19